Nikolaos Tsesmetzis

STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer

J. Bergh, C. Rolny, G. Rassidakis, 2019, Cancers.

Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism

Nikolas Herold, S. G. Rudd, N. Tsesmetzis, 2018, Cancers.

PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma

D. Grandér, K. Young, L. Kis, 2017, Leukemia.

Ribonucleotide reductase inhibitors suppress SAMHD1 ara‐CTPase activity enhancing cytarabine efficacy

H. Qian, R. Schinazi, S. Lehmann, 2020, EMBO molecular medicine.

Potential role of AKT/mTOR signalling proteins in hairy cell leukaemia: association with BRAF/ERK activation and clinical outcome

K. Konstantopoulos, G. Rassidakis, P. Korkolopoulou, 2016, Scientific Reports.

ALK+ Anaplastic Large Cell Lymphoma (ALCL)-Derived Exosomes Carry ALK Signaling Proteins and Interact with Tumor Microenvironment

G. Rassidakis, A. Eliopoulos, E. Drakos, 2020, Cancers.

Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial

R. Schinazi, L. Saft, M. Jädersten, 2022, Journal of internal medicine.

CD274 (PD‐L1)/PDCD1 (PD‐1) expression in de novo and transformed diffuse large B‐cell lymphoma

A. Kwiecińska, L. Saft, L. Kis, 2018, British journal of haematology.